J. Craig Venter Institute, also known as JCVI, is a privately owned, US-based research institute founded in 1992, employing approximately 200 individuals. The institute specializes in biotechnology research, primarily focusing on genomic research.
On March 29, 2026, scientists announced the development of a validated 4D whole-cell simulation of the minimal bacterium JCVI-syn3A, which reproduces a complete cell cycle in space and time. This "digital cell" functions as a working digital twin, enabling researchers to analyze metabolism, DNA replication, gene expression, and division. Previously, on March 25, researchers reported on bioRxiv their success in resurrecting "dead" bacterial cells through the transplantation of complete genomes from other species. This involved replacing the defunct DNA of *Mycoplasma capricolum* bacterial cells with an engineered genome from *Mycoplasma mycoides*, marking the creation of the first living synthetic cells from non-living parts. This technique could facilitate endowing cells with traits for applications such as drug production or biofuel synthesis.
Similar Companies
Subscribe for full access to J. Craig Venter Institute (JCVI)'s profile
Subscribe for full access to J. Craig Venter Institute (JCVI)'s products in full detail
Subscribe for full access to J. Craig Venter Institute (JCVI)'s revenue in full detail
Subscribe for full access to J. Craig Venter Institute (JCVI)'s products in full detail 
